Contact Us
Drug Search Results
More Filters [+]

Ulotaront

Alternative Names: ulotaront, sep-363856, sep363856, sep 363856
Latest Update: 2024-11-13
Latest Update Note: Clinical Trial Update

Product Description

For schizophrenia and parkinson's disease psychosis (Sourced from: https://www.sumitomo-pharma.com/rd/clinical/pipeline.html)

Mechanisms of Action: 5-HT1A Agonist,TAAR1 Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Otsuka
Company Location: NEW YORK NY 10271
Company CEO:
Additonal Commercial Interests: Sunovion

Clinical Description

Map of Global Clinical Trials for Ulotaront

Countries in Clinic: Bulgaria, China, Colombia, Croatia, Czech Republic, Estonia, Finland, Germany, Hungary, Japan, Latvia, Malaysia, Philippines, Poland, Romania, Russia, Serbia, Slovakia, Spain, Sweden, Taiwan, Ukraine, United Kingdom, United States

Active Clinical Trial Count: 23

Highest Development Phases

Phase 3: Depressive Disorder, Major|Generalized anxiety disorder|Schizophrenia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
jRCT2071210003

P3

Recruiting

Schizophrenia

2025-09-30

SEP361-226

P3

Unknown Status

Generalized anxiety disorder

2025-08-26

NCT05593029

P3

Recruiting

Depressive Disorder, Major

2025-05-01

95%
jRCT2031220039

P3

Recruiting

Schizophrenia

2025-03-31

Recent News Events

Date

Type

Title

05/06/2024

PubMed

 Advancements in Non-Dopaminergic Treatments for Schizophrenia: A Systematic Review of Pipeline Developments.

04/23/2024

PubMed

 The trace amine-associated receptor 1 agonists - non-dopaminergic antipsychotics or covert modulators of D2 receptors?

04/23/2024

PubMed

 Beyond dopamine: Novel strategies for schizophrenia treatment.

09/25/2023

News Article

 Generalized Anxiety Disorder Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)

07/10/2023

News Article

 Sumitomo Pharma America Launches as New Combined Organization with Expanded Scale, Resources & Capabilities

04/26/2023

News Article

 Sunovion and Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder

04/06/2023

News Article

 PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions